Albireo’s rare liver disease drug Bylvay scores back-to-back approvals in U.S., Europe

With a pair of approvals on both sides of the Atlantic, liver disease-focused biotech Albireo is off and running with its new medicine Bylvay. The oral drug, the first treatment for pruritus in patients with progressive familial intrahepatic cholestasis (PFIC), scored an FDA nod Tuesday and a European approval Monday. With the FDA’s blessing, Albireo is kicking off an “immediate”… Read More »

New drug Trodelvy gives hope in fight against deadly triple-negative breast cancer

New drug gives hope in fight against one of the deadliest breast cancers… but will it get the green light in time to save these women? Nicola Tracey was diagnose with triple-negative breast cancer in July 2018 Returned in January and she had to tell her daughters she had months to live Philipa Heatherington was… Read More »

Four to enjoy: what to drink this week

DryJuly just got a lot more interesting with the discovery of Plus & Minus wines. Many alcohol-free wines I’ve sampled struggle to have more substance than cordial, but this shiraz might be the go-to red even when the month is over. The fruit is sourced from vineyards in Langhorne Creek, South Australia, and the difference… Read More »

FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults

FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults KENILWORTH, N.J.–(BUSINESS WIRE)– (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive… Read More »